Curcumenol derivative with treatment effect on acute lung injury
By combining curcuminol with succinic anhydride and generating curcuminol monoester sodium salt, GSK3β expression inhibits mTOR signaling pathway, the problems of poor water solubility and unclear mechanism of action are solved, and effective for acute lung injury is achieved In treatment, GSK3β has become a new therapeutic target.
Patent Information
- Application Number
- CN202411013077.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-07-26
AI Technical Summary
The poor water solubility and unclear mechanism of action of curcuminol in the treatment of acute lung injury limit its clinical application.
By combining the curcuminol with succinic anhydride to form the curcuminol monoester I-1 and reacting with sodium bicarbonate solution to form the curcuminol monoester sodium salt II, which regulates the expression of GSK3β to inhibit the activation of the mTOR signaling pathway. This will play a role in treating acute lung injury.
The pulmonary inflammation was significantly reduced at the 5 mg/kg dose, which was better than dexamethasone. It determined that GSK3β was the direct target of sodium salt II of curcuminol succinate, providing a new strategy for the treatment of acute lung injury.
Smart Images

Figure CN119039314A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of preparation of curcuminol derivatives, and particularly relates to curcuminol derivatives having a therapeutic effect on acute lung injury and a preparation method thereof. Background Art
[0002] Acute lung injury (ALI) is a common and complex clinical syndrome in critically ill patients. It usually progresses to acute respiratory distress syndrome (ARDS), is characterized by rapid onset, is often accompanied by non-cardiogenic pulmonary edema and persistent hypoxemia, and may lead to fatal respiratory failure. Due to the high prevalence and mortality of ALI / ARDS, it is very important to determine the causes of ALI / ARDS and find appropriate treatments. At present, no specific drugs for the treatment of acute lung injury have been found. Giving anti-inflammatory drugs from the perspective of suppressing inflammation is a potential treatment method to improve acute lung injury.
[0003] Curcumol is one of the main active ingredients in the traditional Chinese medicine Curcuma, which has shown good anti-inflammatory activity and can regulate multiple signaling pathways such as JAK1 / STAT3, PI3K / Akt / NF-kB, TGF-β1 / Smads, etc. In the treatment of lung diseases, curcumol also has certain potential, which can affect the development process of asthma and promote cell apoptosis. Its mechanism of action is mainly related to inhibiting the activation of the ERK / CREB pathway. Curcumol also has a certain therapeutic effect on chronic asthma, which can reduce lung inflammation in chronic asthmatic mice and inhibit the abnormal activation of the Wnt / β-catenin pathway. Studies have also found that curcumol has good potential in the treatment of acute lung injury. Curcumol made into powder inhaler can effectively reduce the expression of inflammatory factors in ALI rats, which is equivalent to the effect of dexamethasone.
[0004] Although curcumol has certain potential in treating acute lung injury, its water solubility is extremely poor, which greatly inhibits its clinical application. In addition, the mechanism and molecular target of curcumol in treating acute lung injury are still unclear and need further study. In order to solve the above problems, a curcumol derivative with therapeutic effect on acute lung injury and a preparation method are proposed to solve the above problems. Summary of the invention
[0005] The purpose of the present invention is to provide a curcuminol derivative having a therapeutic effect on acute lung injury and a preparation method thereof, so as to solve the problems raised in the above-mentioned background technology.
[0006] To achieve the above object, the present invention provides the following technical solution: a curcuminol derivative having a therapeutic effect on acute lung injury and a preparation method thereof, wherein the curcuminol derivative has the following structure:
[0007]
[0008] Preferably, the synthetic route of the curcumol derivative is as follows:
[0009]
[0010] A method for preparing the above-mentioned curcumol derivative comprises the following steps:
[0011] S1: dissolving curcumol in tetrahydrofuran, evacuating the air in the reaction apparatus, and adding nitrogen into the reaction apparatus to fill the reaction apparatus with nitrogen;
[0012] S2: then adding ethylmagnesium bromide and refluxing at a first preset temperature for 30 minutes;
[0013] S3: then add succinic anhydride and reflux at a second preset temperature for 4 hours;
[0014] S4: Add water to stop the reaction and adjust Ph=4 with hydrochloric acid;
[0015] S5: After extraction with ethyl acetate, the upper layer was purified by a preset method to obtain a yellow oil Ⅰ-1;
[0016] S6: reacting curcumin succinate monoester I-1 with 5% sodium bicarbonate solution, and spinning the solvent to obtain curcumin succinate monoester sodium salt II.
[0017] Preferably, in S1, the added amount of curcumol is 0.4 mmol.
[0018] Preferably, in S1, the amount of tetrahydrofuran added is 2.5 mL.
[0019] Preferably, in S2, the added amount of ethylmagnesium bromide is 0.4 mmol.
[0020] Preferably, in S2, the first preset temperature is 55°C.
[0021] Preferably, in S2, the first preset temperature is 75°C.
[0022] Preferably, in S3, the added amount of succinic anhydride is 1.2 mmol.
[0023] Preferably, in S5, the yield of the yellow oily substance Ⅰ-1 is 82%.
[0024] Preferably, in S5, the preset method is silica gel column chromatography.
[0025] Compared with the prior art, the present invention has the following beneficial effects:
[0026] The raw material medicine used in the present invention has wide clinical application, safety and low toxicity. The hydroxyl group of curcumol is combined with succinic anhydride through a Grignard reaction to form curcumol succinate monoester I-1, which is then reacted with a 5% sodium bicarbonate solution to obtain curcumol succinate monoester sodium salt II. At a dose of 5 mg / kg, LPS-induced acute lung injury can be improved and lung inflammation can be alleviated. Through proteomics, molecular docking, cell thermal transfer experiments and protein imprinting experiments, it is determined that curcumol succinate monoester sodium salt II mainly regulates the expression of GSK3β to inhibit the activation of the mTOR signaling pathway, thereby playing a role in treating acute lung injury. GSK3β is the direct action target of curcumol succinate monoester sodium salt II. The present invention demonstrates the potential of curcumol succinate monoester II as a lead compound in the treatment strategy of acute lung injury. GSK3β is expected to become a new target for treating ALI, providing ideas for developing anti-ALI specific drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 Schematic diagram of the H NMR spectrum of curcumol succinate monoester Ⅰ-1 of the present invention;
[0028] Figure 2 Schematic diagram of the NMR carbon spectrum of curcumol succinate monoester Ⅰ-1 of the present invention;
[0029] Figure 3 This is a schematic diagram of the high-resolution mass spectrum of curcuminol succinate monoester I-1 of the present invention;
[0030] Figure 4 Schematic diagram of the experimental results of the proteomics analysis and western blotting experiments of the present invention;
[0031] Figure 5 These are the experimental results of the molecular docking analysis and cell thermal shift experiment of the present invention. DETAILED DESCRIPTION
[0032] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0033] See also Figure 1-Figure 5 As shown, the present invention provides the following technical solutions:
[0034] Example 1: Synthesis of Curcuma alcohol succinate sodium salt II:
[0035] Curcuma alcohol derivatives with the effect of treating acute lung injury, succinic anhydride and the hydroxyl group of curcuma alcohol are combined by Grignard reaction to form curcuma alcohol succinic acid monoester Ⅰ-1. Then it reacts with 5% sodium bicarbonate solution to obtain curcuma alcohol succinic acid monoester sodium salt Ⅱ;
[0036] In addition, in the present invention, the synthesis route of the above-mentioned curcuminol succinate sodium salt is as follows:
[0037]
[0038] Furthermore, in the present invention, regarding the preparation method of curcumol succinic acid monoester I-1, the preparation method is as follows:
[0039] 0.4 mmol of curcumin was dissolved in 2.5 mL of tetrahydrofuran, the air in the reaction device was evacuated, the device was filled with nitrogen, and then 0.4 mmol of ethylmagnesium bromide was added, and refluxed at 55°C for 30 min, and then 1.2 mmol of succinic anhydride was added, and refluxed at 75°C for 4 h. Water was added to stop the reaction, and Ph was adjusted to 4 with hydrochloric acid. After extraction with ethyl acetate, the upper layer was purified by silica gel column chromatography to obtain a yellow oily substance Ⅰ-1, and the yield of the yellow oily substance Ⅰ-1 was 82%. Then, curcumin succinic acid monoester Ⅰ-1 was dissolved in an equimolar amount of 5% sodium bicarbonate solution to obtain curcumin succinic acid monoester sodium salt Ⅱ.
[0040] In addition, in the present invention, the nuclear magnetic resonance and high-resolution mass spectrometry data of curcumin succinate monoester I-1 are as follows: 1H NMR (600MHz, CDCl3) δ4.89-4.85(m,2H,H-14),2.70-2.58(m,4H,H-2',H-3'),2.51(d,J=14.7Hz,1H, H-9a),2.34(td,J=11.9,11.2,6.4Hz,1H,H-9b),2.22-2.11(m,2H,H-1,H-6a),1.99-1.64(m,5H,H-2 a,H-3a,H-4,H-7,H-11),1.55-1.45(m,1H,H-2b),1.29-1.24(m,1H,H-3b),1.15(dd,J=12.3,6.5Hz, 1H,H-6b),1.00(d,J=6.6Hz,3H,H-15),0.94(d,J=6.4Hz,3H,H-12),0.86(d,J=6.5Hz,3H,H-13).13C NMR(150MHz, CDCl3)δ177.55(C-1'),169.36(C-16),144.43(C-10),113.1 8(C-14),109.40(C-8),89.73(C-5),54.55(C-1),51.61(C-7),39.42(C-4) ,36.82(C-9),33.49(C-6),30.86(C-3),30.26(C-3'),28.64(C-2'),28.34 (C-2,C-11),22.79(C-13),21.37(C-12),12.22(C-15).HR-MS(ESI):Calcd for C 19 H 27 O5(MH):335.1858; found:335.1855.
[0041] In addition, in order to verify the effect of curcumin succinate monoester sodium salt II on improving LPS-induced acute lung injury, the verification method is as follows:
[0042] Example 1
[0043] First, 36 C57BL / 6 male mice were selected. After one week of adaptation, they were randomly divided into 6 groups (n=6), namely control group, model group, high, medium and low dose groups of curcumin succinate sodium salt II (50, 25, 5 mg / kg) and dexamethasone group (DEX, 5 mg / kg). The mice were anesthetized by intraperitoneal injection of 1 μL / g tribromoethanol, and then 50 μL of LPS with a concentration of 15 mg / kg was instilled into the trachea. The control group was instilled with normal saline. 2 hours after LPS modeling, the high, medium and low dose groups of curcumin succinate sodium salt II and the dexamethasone group were injected with the corresponding dose of drugs through the tail vein, and the control group and the model group were injected with the same volume of normal saline. The mice were killed 24 hours after LPS administration, and the alveolar lavage fluid was collected for use.
[0044]
[0045] Table 1
[0046] The results are shown in Table 1. Curcuma succinate monoester sodium salt II can inhibit the expression of inflammatory factors in the bronchoalveolar lavage fluid of mice with LPS-induced acute lung injury. At a dose of 5 mg / kg, it can significantly reduce the expression of TNF-α, IFN-γ and IL-17A, which is better than the positive drug dexamethasone (DEX).
[0047] In addition, in order to verify the mechanism and molecular targets of curcumin succinate monoester sodium salt II in the treatment of acute lung injury determined by proteomics analysis and protein imprinting experiments, the verification method is as follows:
[0048] Example 2
[0049] 4D-label-free proteomics analysis of mouse lung tissue with LPS-induced acute lung injury, including protein extraction, peptide digestion, data acquisition and database retrieval. Liquid chromatography-tandem MS (LC-MS / MS) analysis was performed on a timsTOFPro mass spectrometer (Bruker) coupled to a Nanoelute (Bruker). The mass spectrometry data were qualitatively and quantitatively analyzed using MaxQuant 1.6.14 software. In the screening of significantly differentially expressed proteins, proteins with an expression fold greater than 1.15 times and a P value < 0.05 were selected.
[0050] Proteomics was used to identify the lung tissues of the control group, model group and curcumin succinate monoester sodium salt II-induced ALI mice, and 5383 differentially expressed proteins were found ( Figure 4 A), among which, there were 292 differentially expressed proteins in curcuminol succinate sodium salt II compared with the model group ( Figure 4B). GO functional analysis revealed that curcumin succinate sodium salt II was mainly involved in metabolic processes, biological regulation of biological processes, and responses to stimuli ( Figure 4 C), KEGG pathway enrichment analysis revealed that the mTOR signaling pathway may be a potential pathway for curcumin succinate monoester sodium salt II to exert its anti-inflammatory activity ( Figure 4 D). In the mTOR pathway, compared with the model group, curcumin succinate sodium salt II upregulated the protein expression of GSK3β, and it is speculated that it plays a role in treating acute lung injury by regulating GSK3β. The results of WB experiments showed that curcumin succinate sodium salt II can upregulate the expression of GSK3β and inhibit the expression of S6K protein downstream of the mTOR signaling pathway, indicating that curcumin succinate sodium salt II can regulate the expression of GSK3β, thereby inhibiting the activation of the mTOR signaling pathway ( Figure 4 E).
[0051] In addition, in order to verify that molecular docking analysis and cell thermal shift experiments showed that GSK3β was the direct target of curcumin succinate sodium salt II, the verification method was as follows:
[0052] Example 3
[0053] Molecular docking analysis: Discovery Studio software (version v19.1.0.18287) was used to evaluate the potential interaction between the target compound and the protein GSK-3β. The CDOCKER module in the receptor-ligand interaction module was used for molecular docking operations, and the lowest binding energy and the best binding site of the two were finally obtained. The results of molecular docking and 2D images were also generated using Discovery Studio.
[0054] Cellular thermal shift assay (CETSA) RAW264.7 cells were diluted to a density of 2×106, seeded in 6-well plates and cultured for 24 hours, then treated with curcuminol succinate sodium salt II (50 μM) for 12 hours, and an equal volume of DMSO was added to the control group. The cells were heated for 3 minutes at a certain temperature range, then lysed, centrifuged, and the GSK3β levels in these samples were evaluated using Western blotting (WB).
[0055] Depend on Figure 5 It can be seen that the molecular docking results show that curcumin succinate sodium salt II has a good binding affinity with GSK3β, with a binding free energy of -32.3184 kcal / mol. The terminal carbonyl group of curcumin succinate sodium salt II has a strong hydrogen bond with LEU-88 ( Figure 5A&B). In the CETSA experiment, as the temperature increased, GSK3β in the DMSO group began to degrade at 55°C, while curcuminol succinate sodium salt II maintained the stability of GSK3β at high temperatures and prevented its thermal degradation more effectively than the DMSO group ( Figure 5 C). This result further verified the prediction of molecular docking analysis, indicating that GSK3β is the direct target of curcumin succinate monoester sodium salt II in the treatment of LPS-induced ALI, providing a new idea for the subsequent research on specific drugs for the treatment of ALI.
[0056] The present invention selects curcumin, which is widely used in clinical practice, safe and low in toxicity, and combines the hydroxyl group of curcumin with succinic anhydride through a Grignard reaction to obtain curcumin succinic acid monoester I-1, which is then reacted with a 5% sodium bicarbonate solution to obtain curcumin succinic acid monoester sodium salt II. The synthesis method has universality, short reaction time and high yield. It can play a role in treating acute lung injury at a dose of 5 mg / kg, which is better than the positive drug dexamethasone. Through proteomics, molecular docking, cell thermal transfer experiments and protein imprinting experiments, it is determined that curcumin succinic acid monoester sodium salt II inhibits the activation of the mTOR signaling pathway to play a role in treating acute lung injury, and GSK3β is its direct target. The present invention introduces a curcumin derivative with the effect of treating acute lung injury, and finds that GSK3β is a new target for treating acute lung injury, which lays the foundation for further developing more valuable anti-inflammatory lead compounds, and provides ideas for the development of specific drugs for treating acute lung injury.
[0057] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A curcuminol derivative having a therapeutic effect on acute lung injury, characterized in that: The curcuminol derivative has the following structure:
2. The curcumol derivative having a therapeutic effect on acute lung injury according to claim 1, characterized in that: The synthetic route of the curcuminol derivative is as follows:
3. A method for preparing the curcumol derivative according to claim 1, characterized in that: The steps include: S1: dissolving curcumol in tetrahydrofuran, evacuating the air in the reaction apparatus, and adding nitrogen into the reaction apparatus to fill the reaction apparatus with nitrogen; S2: then adding ethylmagnesium bromide and refluxing at a first preset temperature for 30 minutes; S3: then add succinic anhydride and reflux at a second preset temperature for 4 hours; S4: Add water to stop the reaction and adjust Ph=4 with hydrochloric acid; S5: After extraction with ethyl acetate, the upper layer was purified by a preset method to obtain a yellow oil Ⅰ-1; S6: reacting curcumin succinate monoester I-1 with 5% sodium bicarbonate solution, and spinning the solvent to obtain curcumin succinate monoester sodium salt II.
4. The method for preparing a curcumol derivative according to claim 3, characterized in that: In the S1, the added amount of curcumol is 0.4 mmol.
5. The method for preparing a curcumol derivative according to claim 3, characterized in that: In the S1, the added amount of tetrahydrofuran is 2.5 mL.
6. The method for preparing a curcumol derivative according to claim 3, characterized in that: In the S2, the added amount of the ethylmagnesium bromide is 0.4 mmol.
7. The method for preparing a curcumol derivative according to claim 3, characterized in that: In S2, the first preset temperature is 55°C.
8. The method for preparing a curcumol derivative according to claim 4, characterized in that: In S2, the first preset temperature is 75°C.
9. The method for preparing a curcumol derivative according to claim 3, characterized in that: In the S3, the added amount of succinic anhydride is 1.2 mmol.
10. The method for preparing a curcumol derivative according to claim 3, characterized in that: In the S5, the yield of the yellow oil Ⅰ-1 is 82%.
11. The method for preparing a curcumol derivative according to claim 3, characterized in that: In S5, the preset method is silica gel column chromatography.
Citation Information
Patent Citations
Curcumol hapten and artificial antigen as well as preparation method thereof
CN101671345A
Method of synthesizing curcumol hapten and complete antigen
CN106632385A
Curcumol derivative, preparation method and application thereof
CN106800560A
Curcumenol ester, preparation method and application of curcumenol ester in medicine for treating colorectal cancer
CN113336765A
Novel curcumenol derivatives
CN1704417A
Cited By
Curcumenol derivative containing triazole structure, synthesis method and application of curcumenol derivative in preparation of anti-inflammatory drugs
CN120118094A
Curcumol derivatives containing triazole structure, synthesis method and application thereof in preparing anti-inflammatory drugs
CN120118094B
